November 2022

Efficacité et sécurité des interventions non pharmacologiques et non biologiques : Une revue systématique de la littérature pour la mise à jour 2022 des recommandations ASAS/EULAR pour la prise en charge de la spondylarthrite axiale

Ann Rheum Dis 2022; online ahead of print doi:10.1136/ard-2022-223297

Non-pharmacological interventions are important for any rheumatic disease, but especially axSpA, where they represent the cornerstone of treatment. The aim of this study was to produce a systematic literature review on efficacy and safety of non-pharmacological and non-biological pharmacological treatments was performed.

Keywords:

Efficacité et sécurité de l'upadacitinib chez les patients atteints de rhumatisme psoriasique : résultats à deux ans de l'étude de phase 3 SELECT-PsA 1

Rheumatol Ther. 2022 Oct 15:1–18 doi: 10.1007/s40744-022-00499-w

Results from the long-term extension of SELECT-PsA 1 show efficacy responses similar or greater with upadacitinib, 15 or 30mg, versus adalimumab through 104 weeks.

Keywords:

October 2022

Efficacité du certolizumab pegol chez les patients atteints de spondyloarthrite axiale non radiographique, stratifiée en fonction de l'IRM de la protéine C-reactive de départ : Analyse de l'étude C-axSpAnd

ACR Open Rheumatol. 2022 doi: 10.1002/acr2.11469

The results of this analysis indicated that certolizumab pegol (CZP) treatment benefits patients with nr-axSpA across all the MRI/CRP subgroups studied. To reach this conclusion, this study evaluated clinical responses to CZP in patients with nr-axSpA stratified by baseline MRI/CRP status.

August 2022

Upadacitinib pour le traitement de la spondylarthrite axiale active non radiographique (SELECT-AXIS 2) : Essai de phase 3 randomisé, en double aveugle, contrôlé par placebo

Lancet 2022 doi: 10.1016/S0140-6736(22)01212-0

Upadacitinib significantly improved the signs and symptoms of nr-axSpA compared with placebo at Week 14 in this investigation. Prior to this, upadacitinib had been shown to be effective in patients with AS. This study aimed to assess the efficacy and safety of upadacitinib in non-radiographic axial spondyloarthritis.

Keywords:

June 2022

Caractéristiques de départ et réponse au traitement par Ixekizumab, classées par sexe, dans la spondylarthrite axiale radiographique et non radiographique pendant 52 semaines : Données de trois essais de phase III randomisés et contrôlés

Advance Therapy,2022 Jun;39(6):2806-2819. doi.org/10.1007/s12325−022−02132−2

van der Horst-Bruinsma et al., carried out a post-hoc analysis to confirm that the clinical presentations and responses to ixekizumab therapy may differ in male and female patients.

Keywords:

Ixekizumab dans la spondyloarthrite axiale radiographique avec et sans protéine C-réactive élevée ou imagerie par résonance magnétique positive

Rheumatology Expert, 2022 DOI: 10.1093/rheumatology/keac104

Maksymowych et al., evaluated the efficacy of Ixekizumab in patients with radiographic axial spondyloarthritis (r-axSpA) with and without objective measures of inflammation.

Keywords:

Effets de la thérapie anti-TNF sur les lésions inflammatoires, structurelles et ostéoblastiques dans la spondyloarthrite axiale radiographique - une étude prospective de preuve de concept utilisant la TEP/IRM de l'articulation sacro-iliaque et de la colonne vertébrale

Arthritis Rheumatol. 2022 doi: 10.1002/art.42149

Bruckmann et al carried out this observational, proof of concept study to analyse the effect anti-TNF-therapy (TNFi) on inflammatory, structural, and osteoblastic activity lesions in radiographic axial spondyloarthritis (r-axSpA).  

Keywords:

March 2022

L'effet du sécukinumab sur les résultats rapportés par les patients atteints de rhumatisme psoriasique actif dans un essai randomisé de phase 3

Lancet. 2022. Epub ahead of print

Predefined analysis of FUTURE 5, the largest Phase 3 randomised trial of secukinumab in patients with PsA to date, demonstrates that secukinumab results in early, statistically significant, clinically meaningful, sustained improvements in PROs across all doses, compared with placebo.The fully human anti-interleukin 17A monoclonal antibody, secukinumab has shown clinical and radiographical efficacy in patients with PsA, yet the clinical significance of improvements across a wide variety of PROs r...

Keywords:

Le baricitinib renforce les effets modificateurs de la maladie en dissociant le lien entre l'activité de la maladie et la progression de la structure articulaire chez les patients atteints de polyarthrite rhumatoïde

Ann Rheum Dis. 2022. Epub ahead of print doi: 10.1136/annrheumdis-2021-221323

Baricitinib reduces structural damage progression versus placebo with background MTX and/or MTX, even in patients with moderate or high disease activity.In patients with RA, TNFi, IL-6i and rituximab have been shown to uncouple the link between disease activity and radiographic progression such that patients are protected from structural damage progression even if remission/low disease activity is not achieved.As such, Lopez-Romero, et al. aimed to evaluate if baricitinib further enhances diseas...

Keywords:

January 2022

Inhibition de la progression des lésions articulaires structurelles avec l'upadacitinib dans la polyarthrite rhumatoïde : résultats à un an du programme de phase 3 SELECT

Rheumatology (Oxford). 2021. Epub ahead of print. doi: 10.1093/rheumatology/keab861

.

Keywords: